Is lemborexant safe during the third trimester of pregnancy and while breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lemborexant Safety in Late Pregnancy and Lactation

Lemborexant should be avoided during the third trimester of pregnancy due to lack of safety data, and can be used cautiously during lactation given the minimal drug transfer into breast milk (RID 1.96%).

Pregnancy (Third Trimester)

There is no available safety data for lemborexant use during pregnancy. The FDA drug label does not provide pregnancy-specific guidance 1. Following the principle established in rheumatology guidelines, drugs with insufficient safety data should be avoided during pregnancy until further evidence becomes available 2.

Key Considerations:

  • No human pregnancy data exists for lemborexant
  • As a small molecule dual orexin receptor antagonist, lemborexant likely crosses the placenta
  • The 2020 ACR guideline explicitly states that small molecules are likely to pass through the placenta and notes no available evidence regarding safety of new small-molecule agents during pregnancy 3
  • Risk-benefit assessment: Given insomnia is not life-threatening and alternative pregnancy-compatible approaches exist (behavioral interventions, certain antihistamines), the lack of safety data mandates avoidance

Lactation

Lemborexant can be considered during breastfeeding with appropriate counseling, though caution is warranted given limited data.

Evidence Supporting Use:

A 2024 pharmacokinetic study in healthy lactating women demonstrated 4:

  • Relative Infant Dose (RID): 1.96% of maternal weight-adjusted dose
  • Mean cumulative excretion: only 0.174% of the 10 mg maternal dose appeared in breast milk over 10 days
  • Approximately 70% of excreted drug accumulated within first 24 hours
  • Well below the 10% RID threshold generally considered acceptable for breastfeeding
  • Drug was well-tolerated with only mild adverse events

Clinical Approach:

  • The extremely low RID (1.96%) suggests minimal infant exposure
  • This falls into the category of drugs with "very low levels in breast milk and no evidence of harm" similar to the framework used for other medications with limited lactation data 2
  • Timing strategy: If using lemborexant, consider taking dose immediately after breastfeeding and before longest infant sleep interval to minimize exposure
  • Monitor infant for excessive sedation or poor feeding

Important Caveats:

  • Data is from single-dose study; chronic use patterns may differ
  • Premature or ill infants may have reduced drug clearance
  • Consider non-pharmacologic interventions first (sleep hygiene, cognitive behavioral therapy for insomnia)
  • If insomnia is severe and impacting maternal function/safety, the low RID supports use over untreated maternal sleep deprivation

The contrast between pregnancy and lactation recommendations reflects the fundamental difference: in pregnancy, the drug likely crosses to the fetus with unknown effects, while in lactation, quantifiable minimal transfer (1.96% RID) provides reassurance of safety 4.

Related Questions

What are the risks and benefits of Dayvigo (lemborexant)?
Is Dayvigo (lemborexant) covered by my insurance?
Can I add another hypnotic medication to Dayvigo (lemborexant) 10 mg nightly if it is not effective?
In an adult patient with chronic insomnia, which is more appropriate: Belsomra (suvorexant) or Dayvigo (lemborexant), considering the pattern of sleep disturbance, hepatic function, and risk of next‑day sedation?
In a 71-year-old patient who has not responded to lemborexant 5 mg after an adequate trial and has no contraindications, can the dose be increased to 10 mg?
In a 30-year-old man with a one-week history of left second metacarpophalangeal joint monoarthritis after a gout flare, CT shows erosions of the second metacarpal head, soft‑tissue swelling, joint effusion, periosteal reaction, and an old cortical irregularity of the fifth metacarpal—what is the most likely diagnosis, should MRI be obtained, and is orthopaedic referral indicated?
When should mini‑heparin (subcutaneous unfractionated heparin) be dosed at 5,000 U twice daily versus 2,500 U twice daily for venous thrombo‑embolism prophylaxis, and when is it preferred over enoxaparin (Clexane)?
What are the target serum levels of testosterone, progesterone, and estradiol for a postmenopausal woman on hormone replacement therapy?
In a 64-year-old patient with 2–3 weeks of lower abdominal discomfort, what is the appropriate evaluation and management plan?
In a 70-year-old woman with less than 50% atherosclerotic plaque on computed tomography angiography, should she be started on aspirin and a statin?
What additional work‑up is recommended for a patient with ten‑day diarrhea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.